Published June 3 2014 in What's New

Laval, May 30 2014 –  Ergoresearch Ltd (TSXV: ERG) – based in Laval and mainly known under the Clinique du pied Équilibre, Orthoconcept and Laboratoire Langelier banners – announced today its third quarter results for the period ended March 31, 2014. All figures quoted are in Canadian dollars.

Financial results analysis takes into consideration the acquisitions of Victhom Human Bionics inc. on April 26, 2013.


Revenues for the third quarter of fiscal 2014 were stable and totaled $ 3,823,851 compared to              $ 3,813,863 for the third quarter ended March 31, 2013. Like most companies in the industry, Quebec severe winter affected the performance of all our products, in all our divisions since the majority of our sales are currently generated in Quebec. The increase in sales of our new distraction brace ‘’Odra ‘’ was able to offset this slowdown.


Operating income amounted to $ 248,295 in the third quarter of fiscal 2014 compared to $ 399,873 in the third quarter of fiscal 2013. Depreciation included in the income is $ 252,742 for the current quarter compared to $ 150,294 for the quarter ended March 31, 2013.


For the third quarter of 2014, profit before tax amounted to $ 135,125 compared to $ 312,239 for the corresponding period in 2013. As for EBITDA, it amounted to $ 432,167 compared to $ 476,446 for the third quarter ended March 31, 2013.


Total assets amounted to $33,770,035 for the quarter ended March 31, 2014, company had $9,426,184 cash on hand.


M.Sylvain Boucher, President and CEO of Ergoresearch states: “The third quarter was mainly devoted to integrate recent acquisitions and to develop efficient tools for further expansion. More specifically, the following have been realized including:



o    Hiring an experienced manager as CFO, Mr. Piero Greco

o    Share issuance for gross proceeds of $ 5,000,000

o    Closing of Podotech Laval clinical and transfer of its activities to Orthoconcept Laval.

o    Continued implementation of the new web base ERP software according to plan; to date,           the Company uses concurrently the old and the new system in one of its subsidiaries in order to ensure clinical and production data integrity.


Products have been affected by severe winter weather in 2014 in Quebec since the company currently generates the majority of its revenue. The Company has nevertheless completed the training and ‘‘ODRA’’ certification of a Western Canadian partner. The Company also plans to drive two other tests in Canada by this type of distribution channel during the next year. This validation process is an important step in the deployment of the patented product ”ODRA’’ outside Quebec.

Finally, the company completed last April the development of scanner technology for the orthopedic field. These new 3D scanners come support the launch of the Odra brace has received a warm reception from the patients and the medical community. These 3D scanners, like other tools developed internally, are fully integrated into the new ERP platform.

Ergoresearch is advantageously positioned to execute the next stages of its growth plan. «We will use the coming months to accelerate the commercialization of our products (including new distraction ” Odra ” brace) , unify our brands under a single brand name, while remaining on the lookout for opportunities to acquire businesses. “Says the President and CEO of Ergoresearch , M.Sylvain Boucher.



About Ergoresearch


Ergoresearch is a Canadian based company that designs and manufactures cutting edge technologies for the orthopedic industry.  The Company holds patents in the field of bionics including intellectual property used in the Power Knee, the world’s only motor-powered prosthesis for above-knee amputees.  Ergoresearch has developed and commercialized Web-Fit™, the first robotized custom-fit orthotics manufacturing software program and launched OdrA, a world -patented orthotic device that revolutionizes the treatment of pain associated with knee osteoarthritis

Ergoresearch owns Quebec’s leading network in orthotics, with over 100 corporate and satellite centres under the Clinique du pied Équilibre, Orthoconcept and Laboratoire Langelier banners.  The Company is listed on the TSX Venture Exchange (TSXV) under the symbol ERG.


This is not an invitation to purchase securities listed on TSX Venture Exchange. TMX Group and its affiliates do not endorse or recommend any of the referenced securities or investment advisors. Please seek professional advice to evaluate specific securities.


Forward looking statements

Certain statements in this Press Release contain forward-looking statements and information that may entail certain risks related to uncertainties. Such statements are based on management’s expectations and no assurance can be given that potential future results or circumstances described in the forward looking statements will be achieved or will occur. Such risks factors include, but are not limited to, those related to the Corporation’s ability to finance its activities, competition, ability to negotiate and maintain partnerships, the market acceptance of the said product, fluctuations in operating results, the impact of general economics, industry and market conditions, the ability to recruit and retain qualified employees, the success of research and development programs, fluctuations in cash flow, expectations regarding market demand for particular products, the strength of intellectual property, market dependence on new product development, the trust invested in sub-contractors or their core personnel, as well as other documents containing risks and uncertainties which are put forth every now and then by the firm to various Canadian securities and exchange commissions and made available at

The reader should not give great importance to forward-looking statements as the results may differ from conclusions, predictions or projections contained in such forward-looking statements; and certain important factors or hypothesis taken into account in reaching conclusions or the preparation of a projection or prediction may prove to be incorrect in fact.


Management disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or circumstances. All figures are in Canadian dollars, unless otherwise specified.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Sylvain Boucher, President and CEO – Ergoresearch Ltd
Tel.: 450-973-6700, x. 213 /



Émilie Vion, Communications Coordinator – Ergoresearch Ltd

Tel.: 450-973-6700, x. 242  /


Réalisation Web Sept24